Which Peptide Is Right for Your Research? Full Breakdown Below
GLP-1 based peptides are currently leading the way in weight loss and metabolic research. Among the most discussed are Retatrutide, Tirzepatide (Tirz), and Semaglutide (Sema) — but how do they actually differ?
Let’s take a closer look at their mechanisms, reported effects, and ideal research applications.
Retatrutide –
| For advanced fat-loss/metabolic models
Tirzepatide – | For GLP+GIP dual-pathway studies
Semaglutide – | For stable, long-term baseline research
COAs and lab verification available on request.
All compounds listed here are strictly intended for research use only.
They are not for human consumption or therapeutic/medical use of any kind.
Have you tried any of these in your research?
Drop your feedback or questions below
We’re happy to help clarify mechanisms, supply details, or testing procedures.
GLP-1 based peptides are currently leading the way in weight loss and metabolic research. Among the most discussed are Retatrutide, Tirzepatide (Tirz), and Semaglutide (Sema) — but how do they actually differ?
Let’s take a closer look at their mechanisms, reported effects, and ideal research applications.
Mechanism of Action
- Retatrutide – Triple agonist: GLP-1 + GIP + Glucagon
➤ The newest and most aggressive model peptide in this class. - Tirzepatide – Dual agonist: GLP-1 + GIP
➤ Balanced approach for fat loss and insulin-related studies. - Semaglutide – Single agonist: GLP-1 only
➤ Reliable, stable, and ideal for long-term or comparative research.
Reported Research Outcomes
- Retatrutide:
Most aggressive appetite suppression
Up to 24% body weight reduction in clinical models
Suitable for advanced, short-cycle high-intensity studies - Tirzepatide:
Consistent fat reduction (15–20%)
Weekly protocols, excellent metabolic profile
Good for intermediate research setups - Semaglutide:
10–15% weight loss effect
Fewer GI-related issues
Ideal for beginners and low-intensity studies
Summary Table
Retatrutide –
| For advanced fat-loss/metabolic modelsTirzepatide –
| For GLP+GIP dual-pathway studiesSemaglutide –
| For stable, long-term baseline research
Suggested Research Formats (Most Common)
- Retatrutide: 10mg/vial
- Tirzepatide: 10mg/vial
- Semaglutide: 10mg/vial
COAs and lab verification available on request.
Important Disclaimer
All compounds listed here are strictly intended for research use only.
They are not for human consumption or therapeutic/medical use of any kind.
Let’s Discuss
Have you tried any of these in your research?
Drop your feedback or questions below
We’re happy to help clarify mechanisms, supply details, or testing procedures.
Reduction of Visceral Fat (VAT)